(Q33887755)

29 July 2017

1 reference

title

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. (English)

1 reference

29 July 2017

coronary artery disease

1 reference

3

1 reference

29 July 2017

1

A M Lincoff

1 reference

29 July 2017

2

R M Califf

1 reference

PubMed ID

10758948

29 July 2017

language of work or name

English

0 references

publication date

1 April 2000

1 reference

Journal of the American College of Cardiology

29 July 2017

1 reference

29 July 2017

35

1 reference

29 July 2017

1103-1115

1 reference

29 July 2017

5

1 reference

Are we mortgaging the medical profession?

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Low molecular weight, non-peptide fibrinogen receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Recepto

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Antithrombotic therapy in patients undergoing coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

"Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900554-4

7 January 2021

10.1016/S0735-1097(00)00554-4

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10758948